Aptamer Details

Back to Search Results

Tumor-derived endothelial cells (tRRL) (ID# 7749)

* The secondary structure may not be accurate because of MFOLD limitations on chemistries other than RNA/DNA.

Aptamer Chemistry: Peptide

Target: Tumor-derived endothelial cells (TDECs)

Antigen/Target Category: Cells

Affinity (Kd): N/A nM (reported value)

Binding Conditions/Buffer: PBS was used for Flow Cytometry assays.
For radiometric binding assays, cell media varied according to cell line. See ref. for details.

Binding Temp: N/A°C

Refolding Protocol: NA If the oligo is a known aptamer sequence: For binding studies, perform a refolding protocol to ensure proper function (i.e. binding to antigen or target). Refer to the aptamer reference source for the appropriate refolding parameters and binding conditions. Note: it is unknown whether aptamer functions properly without refolding.

Specificity: Radioactive peptide was taken up by HUVEC, B16, and HepG2 cell lines. It was not taken up by the HK-2 cell line.
Hepatic carcinoma (HepG2) and melanoma (B16) xenograft mice showed tumor labeling using the radioactive peptide.

Sequence ():

Length: 10

Molecular Weight: 1141.4

Note: Information on this aptamer oligo was obtained from the literature and hasn't been validated by Aptagen.

Reference:

X Lu et al. Use of radioiodinated peptide arg-arg-leu targeted to neovascualrization as well as tumor cells in molecular tumor imaging. Chin J Cancer Res 24(2012): 52-59.

Have your aptamer oligo synthesized ORDER